Clinical Trial Update: DV Combined With PD-1 and Platinum-based First-line Treatment in Patients With HER2 IHC2+/3+ ESCC [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for DV in combination with PD-1 and platinum-based first-line therapy in HER2 IHC 2+/3+ esophageal squamous cell carcinoma (Phase 1/2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• DV
• PD-1 inhibitor
• Platinum-based chemotherapy (platinum-based chemotherapy)

Snippet

Sponsor: Changhai Hospital | Conditions: Esophageal Squamous Carcinoma, HER-2 Protein Overexpression | Phase 1, Phase 2 | Status: UNKNOWN